Echenagucia-Echenagucia M

Idioma: Español
Referencias bibliográficas: 22
Paginas: 86-95
Archivo PDF: 298.45 Kb.

RESUMEN

La búsqueda del anticoagulante ideal está orientada a obtener fármacos seguros en su mecanismo de acción, de fácil administración, idealmente con formulación oral, prescritos a dosis fija con efecto predecible e inicio de acción más rápido, con la menor cantidad de efectos secundarios y sin interacciones con otros medicamentos o mecanismos bioquímicos naturales, lo que da lugar al desarrollo de los anticoagulantes orales directos. Esta revisión está centrada en la vigilancia de este tipo de anticoagulantes, por lo que se hace hincapié en cómo orientar la vigilancia, los requerimientos, los métodos utilizados, así como estrategias alternativas para conseguirlo. Por último, cada laboratorio debe tener conocimiento del efecto del anticoagulante oral directo en su sistema de reactivo, a través de revisiones en la bibliografía o muestras de pacientes y debe usar calibradores comerciales y controles con cuidado.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lessire S, Douxfils J, Bausar J. Is Thrombin time useful for the assessment of dabigatran concentrations? Thromb Res 2015;136(3).

2. Levy H, Ageno W, Chan N, et al. Subcommittee on control of anticoagulation. When and how to use antidotes for the reversal of direct anticoagulants guidance from the SSC of the ISTH. Thromb Haemost 2016;14(3).

3. Barret J, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104(6).

4. Barret Y, Wang J, Song Y. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost 2012;107(5).

5. Bathala M, Masumoto H, Oguma T, et al. Pharmacokinetic, biotransformation, and mass balance of endoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012;40(12).

6. Dager W, Gosselin R, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen a multicenter in vitro study. Ann Pharmacother 2012;46(12).

7. DeLavenne X, Mismetti P, Basset T. Rapid determination os apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 2013;78.

8. Douxfills J, Chatelain B, Chatelain C, Dogné J, Mullier F. Endoxaban: Impact on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2016;115(2).

9. Douxfils J, Gosselin R. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost 2017;43.

10. Douxfils J, Moulier F, Dogné J. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110(3).

11. Douxfils J, Tamigniau A, Chatelain B. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/ MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013;110(4).

12. Gosselin R, Adcock D, Hawes E, Francart S, et al. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb Haemost 2015;113(1).

13. Gous T, Couchman L, Patel J, Paradzai C, Arya R, Flanagan R. Measurement of the direct oral anticoagulants apixaban, dabigatran, endoxaban and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 2014;36(5).

14. Harenberg J, Kramer S. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 2014;44(8).

15. Herrera M. Anticoagulantes orales directos: control de laboratorio y actualización de pruebas específicas. Hematología 2018;22.

16. McGrail R, Revsholm J, Nissen P. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res 2016;148.

17. Mueck W, Eriksson B, Bauer K. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor- in patient undergoing major orthopedic surgery. Clin Pharmacokinet 2008;47(3).

18. Robert C, Gosselin D, Adcock S, et al. International Council for Standardization in Haematology: Recommendation for Laboratory measurement of Direct Oral Anticoagulants. Thromb Haemost 2018;118.

19. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23(2).

20. Strangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64(3).

21. Vogeser M, Seger C. Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin Chem 2010;56(8).

22. Zhang L, Long Y, Xiao H, et al. Use of D-dimer in oral anticoagulation Therapy. Int J Lab Hematol 2018;40.